Antibody-drug conjugates for non-oncological indications

Expert Opinion on Biological Therapy

Volumn 16, Issue 5, 2016, Pages 591-593

  Liu, Renhe ^a   Wang, Rongsheng E ^a   Wang, Feng ^a  

^a California Institute for Biomedical Research (Calibr)   (United States)

Author keywords

ADCs; Antibody drug conjugates; non oncology

Indexed keywords

CYTOTOXIC AGENT; DRUG ANTIBODY; ANTIINFECTIVE AGENT; IMMUNOTOXIN;

AUTOIMMUNE DISEASE; CANCER THERAPY; DRUG CONJUGATION; DRUG STRUCTURE; HUMAN; NONHUMAN; REVIEW; TREATMENT INDICATION; DRUG DESIGN; IMMUNOMODULATION;

ANTI-INFECTIVE AGENTS; DRUG DESIGN; HUMANS; IMMUNOMODULATION; IMMUNOTOXINS;

EID: 84961391260     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2016.1161753     Document Type: Review

References (13)

1. Ehrlich P. Zur Kenntnis der Antitoxinwirkung. Fortschr Med. 1897; 15: 41-43.
2. Kamath AV, Iyer S. Preclinical pharmacokinetic considerations for the development of antibody drug conjugates. Pharm Res. 2015; 32: 3470-3479.
3. Sassoon I, Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol Biol. 2013; 1045: 1-27.
4. Graversen JH, Svendsen P, Dagnaes-Hansen F, et al. Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol Ther. 2012; 20: 1550-8.
5. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354: 2531-2541.
6. Giles FJ, ODwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2009; 23: 1698-1707.
7. Wang RE, Liu T, Wang Y, et al. An immunosuppressive antibody-drug conjugate. J Am Chem Soc. 2015; 137: 3229-32.
8. Liu T, Liu Y, Wang Y, et al. Rational design of CXCR4 specific antibodies with elongated CDRs. J Am Chem Soc. 2014; 136: 10557-10560.
9. Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008; 26: 925-32.
10. Axup JY, Bajjuri KM, Ritland M, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A. 2012; 109: 16101-16106.
11. Lim RKV, Yu S, Cheng B, et al. Targeted delivery of LXR agonist using a site-specific antibody-drug conjugate. Bioconjugate Chem. 2015; 26: 2216-2222.
12. Lehar SM, Pillow T, Xu M, et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature. 2015; 527: 323-328.
13. Perez HL, Cardarelli PM, Deshpande S, et al. Antibody-drug conjugates: current status and future directions. Drug Discov Today. 2014; 19: 869-881.